Innovating Works

Biopredic International

Desconocido
halt-RONIN: Discovering chronic inflammation biomarkers that define key stages in the Healthy to NASH non alcoh... BIOPREDIC INTERNATIONAL SARL participó en un HORIZON EUROPE: HORIZON-HLTH-2022-STAYHLTH-02 Non-alcoholic fatty liver disease (NAFLD) is a multifactorial chronic inflammatory disease that is prevalent in 1 of 4 individuals with a si...
2022-11-22 - 2026-11-30 | Financiado
GOLIATH: Beating Goliath Generation Of NoveL Integrated and Internationally Harmonised Approaches for Testi... BIOPREDIC INTERNATIONAL SARL participó en un H2020: H2020-SC1-BHC-2018-2020 GOLIATH addresses the work programme topic ‘SC1-BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (E...
2018-11-21 - 2024-12-31 | Financiado
NOTOX: Predicting long term toxic effects using computer models based on systems characterization of organo... BIOPREDIC INTERNATIONAL SARL participó en un FP7: NOTOX will develop and establish a spectrum of systems biological tools including experimental and computational methods for i) organotypic...
Financiado
BALANCE: Development of a bioartificial liver therapy in acute liver failure BIOPREDIC INTERNATIONAL SARL participó en un FP7: In BALANCE, the companies Hep-Art, Pharmacell and BioPredic join forces with academic partners Amsterdam Medical Centre and University of Ed...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.